Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization

Kim, Nam Hee; Lee, Taeheon; Cho, Yong Kyun; Kim, Byung Ik; Kim, Hong Joo

doi:10.1111/jgh.14083

Cited by 16 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite current advances in the diagnosis of HCC, the majority of patients are not eligible for surgical treatment due to late diagnosis. Moreover, the five-year survival rate of patients undergoing surgical resection is disappointingly low [ 3 ]. Tumor proliferation and apoptosis plays an important role in the occurrence and development of HCC [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation

Liu

Wei

et al. 2018

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundThe sperm-associated antigen 5 (SPAG5) plays a key role in controlling various cellular phenomena, including cell cycle progression and proliferation. However, the role of SPAG5 in hepatocellular carcinoma (HCC) remains unknown.MethodsThis study investigated the function and clinical significance of SPAG5 protein expression in hepatocellular carcinoma. We analyzed SPAG5 expression in surgical specimens from 136 HCC patients. The correlation between the clinical characteristics and prognosis was also determined. Furthermore, the SPAG5 was overexpressed in HCC cell and silenced with shRNA in HCC cells. Moreover, cell proliferation and apoptosis were measured using Edu assay and flow cytometry and a molecular mechanism of SPAG5 promotes HCC progression was explored.ResultsHerein, our study showed that upregulation of SPAG5 was detected frequently in primary HCC tissues, and was associated with significantly worse survival among the HCC patients. Multivariate analyses revealed that high SPAG5 expression was an independent predictive marker for the poor prognosis of HCC. SPAG5 silence effectively abolished the proliferation abilities of SPAG5 in vivo and in vitro, while induced apoptosis in HCC cells. Furthermore, our results indicate that SPAG5 promoted cell progression by decreasing SCARA5 expression, which has been reported to control the progression of HCC, and our data demonstrated that SCARA5 is crucial for SPAG5-mediated HCC cell progression in vitro and in vivo. Moreover, we found that the expression of SPAG5 and SCARA5 are inversely correlated in HCC tissues. In addition, we demonstrated that SPAG5 promoted progression in HCC via downregulating SCARA5 depended on the β-catenin/TCF4 signaling pathway. Interestingly, the underlying mechanism is which SPAG5 regulates SCARA5 expression by modulating β-catenin degradation.ConclusionsTaken together, our data provide a novel evidence for the biological and clinical significance of SPAG5 as a potential biomarker, and we demonstrate that SPAG5-β-catenin-SCARA5 might be a novel pathway involved in HCC progression.Electronic supplementary materialThe online version of this article (10.1186/s13046-018-0891-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation

Liu

Wei

et al. 2018

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Currently, the presence of CSPH precludes patients from undergoing surgical resection for HCC [19], but less attention has been paid to other loco-regional therapies. However, two studies have recently reported that CSPH is a major negative prognostic factor in patients treated with DEB-TACE [10,20].…”

Section: Discussionmentioning

confidence: 99%

“…Considering the heterogeneity of TACE candidates, patient selection must be carefully carried out. Underlying chronic liver disease is exacerbated by this procedure, especially in patients with diminished liver reserve [10]. Several algorithms have been recently reported to predict HCC prognosis in an attempt to optimize chemoembolization treatments, but few data have been obtained from DEB-TACE procedures [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

et al. 2020

View full text Add to dashboard Cite

Background: A single-centre cohort study was performed to identify the independent factors associated with the overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization with drug-eluting beads (DEB-TACE). Methods: A total of 216 HCC patients who underwent DEB-TACE from October 2008 to October 2015 at a tertiary hospital were consecutively recruited. The analysis of prognostic factors associated with overall survival after DEB-TACE, stressing the role of post-TACE events, was performed. Results: The objective response (OR) rate (Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria) to the first DEB-TACE (DEB-TACE-1) was 70.3%; the median OS from DEB-TACE-1 was 27 months (95% confidence interval (CI), 24-30). In the multivariate analysis, tumor size, AFP < 100 ng/mL and serum alkaline phosphatase were independent factors for survival following DEB-TACE-1. The most important clinical event associated with poor survival was the development of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history of ascites, albumin and hemoglobin but not to tumour load or to response to therapy. Conclusions: Early ascites post-DEB-TACE is associated with the survival of patients despite adequate liver function and the use of a supra-selective technical approach. History of ascites, albumin and hemoglobin are major determinants of the development of early ascites post-DEB-TACE.

show abstract

“…For HCC patients with cirrhosis who underwent TACE, Nam Hee Kim et al found that PH was a major negative factor [24]. However, Xiao et al found that hepatectomy provided better long-term prognosis for HCC patients with PH than TACE and ablation [25].…”

Section: Discussionmentioning

confidence: 99%

Hepatectomy Provides Good Long-Term Outcomes for Hepatocellular Carcinoma Patients With Portal Hypertension: A Propensity Score Matching Analysis

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The role of hepatectomy in hepatocellular carcinoma (HCC) with portal hypertension (PH) remains controversial. This study aimed to evaluate the effect of hepatectomy on overall survival (OS) of HCC patients with PH.Methods: A total of 1651 HCC initially treated with hepatectomy were retrospectively reviewed and divided into PH group (n=157) or non-PH group (n=1494). Propensity score matching (PSM) was conducted to match the baseline characteristics of the PH group and non-PH group. Results: The PH group presented a similar OS (p=0.29) and recurrence free survival (RFS) (p=0.83) compared with non-PH group after initial hepatectomy before PSM. After PSM processing, the baseline characteristics were highly comparable for both groups (133 patients in each group). The PH group also presented a similar OS (p=0.81) and RFS (p=0.65) compared with non-PH group after initial hepatectomy. After PSM, multivariate analysis identified tumor size (>5 cm) (p=0.02), macro-venous invasion (p < 0.001), AST (>37 U/L) (p =0.008) as independent risk factors for OS.Conclusions: Hepatectomy provides good long-term outcomes for HCC patients with PH. PH should not be regarded as a contraindication for hepatectomy in HCC patients.

show abstract

Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization

Abstract: The presence of CEPH should be considered as a major negative prognostic factor for patients with HCC who will undergo TACE.

Cited by 16 publications

References 30 publications

SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation

SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation

The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

Hepatectomy Provides Good Long-Term Outcomes for Hepatocellular Carcinoma Patients With Portal Hypertension: A Propensity Score Matching Analysis

Contact Info

Product

Resources

About